Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB

Journal of Dermatological Treatment

Volumn 21, Issue 1, 2010, Pages 45-48

  D'Acunto, Carmine ^a   Gurioli, Carlotta ^a   Neri, Iria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bexarotene; Mycosis fungoides; Narrow band UVB

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; BEXAROTENE; CORTICOSTEROID; GAMMA INTERFERON; RETINOID X RECEPTOR; ANTINEOPLASTIC AGENT; TETRALIN DERIVATIVE;

AGED; ARTICLE; CASE REPORT; CELL PROLIFERATION; CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; RADIATION DOSE; RELAPSE; ULTRAVIOLET B RADIATION; PATHOLOGY; SKIN NEOPLASMS;

AGED; ANTICARCINOGENIC AGENTS; FEMALE; HUMANS; MYCOSIS FUNGOIDES; PUVA THERAPY; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 76749105299     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903103980     Document Type: Article

References (17)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classifcation for cutaneous lymphomas. Blood. 2005;105:3768-3785.
2. Kaye FJ, Bunn PAJr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing electronbeam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J med. 1989;321:1784-1790.
3. Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol. 2002;1:134-136.
4. Pancake BA, Zucker-franklin D, Coutavas EE. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus associated disease. A study of 50 patients. J Clin Invest. 1995;95:547-554.
5. Cheng SX, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:649-652.
6. Lotan R, Clifford JL. Nuclear receptor for retinoids: Mediators of retinoid effects on normal and malignant cells. Biomed Pharmacother. 1991;45:145-156.
7. Szonday A, Reichert U, Fesus L. Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors. Cell Death Differ. 1998;5:4-10.
8. Ginguere V, Ong ES, Segui P, Evans RM. Identifcation of a receptor for morphogen retinoic acid. Nature. 1987;330:624-629.
9. Nawa T, Nawa mt, Cai T, Zhang C, Uchimura I, Narumi S, et al. Repression of TNF-alpha induced E-selectin expression by PPAR activators: Involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun. 2000;275: 406-411.
10. Duvic M, Hymes K, Heald P, Breneman D, martin AG, myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol. 2001;19: 2456-2471.
11. McGinnis KS, Shapiro M, Vittorio CC, rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol. 2003;139:771-775.
12. McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: Clinical synergism and possible immunologic mechanism. J Am Acad Dermatol. 2004;50:375-379.
13. Brash DE, rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP. A role for sunlight in skin cancer: UV-induced p53 mutation in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88:10124-10128.
14. Ullrich SE. Modulation of immunity by ultraviolet radiation: Key on antigen presentation. J Invest Dermatol. 1995;105: (1 suppl)30S-6S.
15. Lokitz ML, Wong HK. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. Photodermatol Photoimmunol Photomed. 2007;23:255-257.
16. Papadavid E, antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, et al. Safety and effcacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol. 2008;9:169-173.
17. Michaelis S, Cozzio A, Kempf W, Graf P, Burg G. Combination of bexarotene and psoralen-UVA. Therapy in a patient with mycosis fungoides. Dermatology. 2004;209:72-74.